METHODS: We performed a meta-analysis using a pre-designed protocol and PRISMA guidelines to evaluate the mean difference between systolic blood pressure before and after administration of the sedative. We also analyzed the relative risks of hypotension.
RESULTS: Ten studies were included. The incidence of hypotension in patients receiving etomidate ranged from 6.4% to 75.2%, and between 24.0% and 65.9% in patients receiving other sedatives. No significant differences were found in the mean difference in systolic blood pressure during pre-intubation 0.01 mm Hg (95% CI: -0.90; 0.92) or in post-intubation 0.98 mmHg (95% CI: -0.24; 2.20). The relative risk analysis showed that the risk of hypotension is equal to an RR of 1.19 (95% CI: 0.92-1.54) between those who received etomidate and those who received the other sedatives.
CONCLUSIONS: The risk of hypotension after rapid intubation sequence with etomidate does not differ significantly compared to other sedatives. However, the studies included in this review were heterogeneous.
方法:我们使用预先设计的方案和PRISMA指南进行了荟萃分析,以评估镇静剂给药前后收缩压之间的平均差异。我们还分析了低血压的相对风险。
结果:纳入10项研究。接受依托咪酯的患者低血压的发生率为6.4%至75.2%,在接受其他镇静剂的患者中,占24.0%至65.9%。插管前0.01mmHg(95%CI:-0.90;0.92)或插管后0.98mmHg(95%CI:-0.24;2.20)的收缩压平均差异无显着差异。相对风险分析显示,低血压的风险等于接受依托咪酯和接受其他镇静剂的患者的RR为1.19(95%CI:0.92-1.54)。
结论:与其他镇静剂相比,依托咪酯快速插管后低血压的风险没有显著差异。然而,纳入本综述的研究具有异质性.